Humacyte, Inc.
For the period ended Dec 31, 2025. Filed Mar 27, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 27, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Act of 1934, as amended, the registrant has duly caused this Annual Report on Form 10-K to be signed on its behalf by the undersigned, thereunto duly authorized.
| HUMACYTE, INC. | |
| By: | /s/ Laura E. Niklason |
| Name: Laura E. Niklason, M.D., Ph.D. | |
| Title: President and Chief Executive Officer |
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this Annual Report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated:
| Name | Position | Date |
|---|---|---|
| /s/ Laura E. Niklason | President, Chief Executive Officer and Director(Principal Executive Officer) | March 27, 2026 |
| Laura E. Niklason, M.D., Ph.D. | ||
| /s/ Dale A. Sander | Chief Financial Officer, Chief Corporate Development Officer and Treasurer | March 27, 2026 |
| Dale A. Sander | (Principal Financial and Accounting Officer) | |
| /s/ Kathleen Sebelius | Director | March 27, 2026 |
| Kathleen Sebelius | ||
| /s/ John Bamforth | Director | March 27, 2026 |
| John Bamforth | ||
| /s/ Emery N. Brown | Director | March 27, 2026 |
| Emery N. Brown, M.D., Ph.D. | ||
| /s/ Michael T. Constantino | Director | March 27, 2026 |
| Michael T. Constantino | ||
| /s/ Brady W. Dougan | Director | March 27, 2026 |
| Brady W. Dougan | ||
| /s/ C. Bruce Green | Director | March 27, 2026 |
| C. Bruce Green, M.D. | ||
| /s/ Keith Anthony Jones | Director | March 27, 2026 |
| Keith Anthony Jones, M.D. | ||
| /s/ Todd M. Pope | Director | March 27, 2026 |
| Todd M. Pope | ||
| /s/ Diane Seimetz | Director | March 27, 2026 |
| Diane Seimetz, Ph.D. | ||
| /s/ Max Wallace | Director | March 27, 2026 |
| Max Wallace, J.D. | ||
| /s/ Susan Windham-Bannister | Director | March 27, 2026 |
| Susan Windham-Bannister, Ph.D. | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.